Patients are not eligible if they have had or are planned for solid organ transplant; patients who have received allogeneic hematopoietic stem cell transplant are eligible if:\r\n* The transplant occurred at least  days prior to registration, \r\n* Patient has no prior acute graft versus host disease (GVHD), and \r\n* Within  hours of registration, patient demonstrates at least % engraftment, defined as: absolute neutrophil count (ANC) >=  mcl, measured over  consecutive days or  day with an ANC >= , mcl, or platelets >= , mcl measured, wherein the patient did not receive any platelet transfusions within  days prior to laboratory assessment
Patients may have received prior allogeneic transplant or autologous transplant; however, patients with prior allogeneic bone marrow transplant will be eligible only if both of the following conditions are met:\r\n* The transplant must have been performed >=  days prior to registration\r\n* The patient must not have >= grade  acute graft versus host disease (GvHD) or either moderate or severe limited chronic GvHD within  days prior to registration
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least  days before date of enrollment; patient must be off immunosuppression and without active graft versus host disease (GVHD) prior to enrollment if previous HSCT
COHORT : Not be appropriate candidate for intensive salvage chemotherapy due to co-morbidities or other disease- or treatment-related factors\r\n* NOTE: Subjects who received prior treatment with hypomethylating agents either for myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), or AML will be eligible\r\n* NOTE: Subjects who had prior allogeneic stem cell transplant (alloHSCT) will be eligible as long as they have been at least  months after allogeneic HSCT and are off of all immune suppression for at least  weeks (> days) and have no evidence of active graft versus host disease (GVHD); subjects with prior alloHSCT will NOT be eligible for enrollment during the safety run in phase
Allogenic or autologous transplant for hematological malignancy with infusion of stem cells within  days before Cycle  Day , or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within  weeks of Cycle  Day .
No prior allogeneic transplant unless all of the following apply:\r\n* At least  years from time of transplant\r\n* Absence of clinically significant graft-versus-host disease (GVHD)\r\n* Not on immune suppression\r\n* Approval of overall PI
Patients with history of allogeneic stem cell transplantation are eligible if at least  days post-transplant, if there is no evidence of active graft versus host disease (GVHD) and no longer taking immunosuppressive agents for at least  days prior to enrollment
Receipt of an allogeneic transplant within  months or an autologous transplant within the preceding  months; evidence of ongoing graft-versus-host disease (GVHD)
For subjects with prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD), and must be >=  weeks off immunosuppressive therapy
Prior allogeneic transplant performed ?  months prior to first dose of AMV is allowed provided there is no evidence of active graft-versus-host disease (GVHD) and the patient has been off immunosuppressive therapy for ?  weeks.
Prior allogeneic transplant if performed <  months prior to first dose of AMV, if patient has active GVHD, or if patient has not been off immunosuppressive
If prior allogeneic stem cell transplant, history of moderate to severe chronic graft versus host disease (GVHD)
Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant, i.e. patients requiring therapy more than chronic steroid immunosuppression and/or phototherapy for chronic skin GVHD will be excluded.
Cohort #: patients with MCL with prior allogeneic hematopoietic stem cell transplant, minimum  months after transplant, not on immunosuppression, and without prior or active graft versus host disease (GVHD), are allowed
Patients within  year of allogeneic stem cell transplant, patients with active graft versus host disease (GVHD) or requiring immunosuppression are excluded
No evidence of active graft-versus-host disease (GVHD) and at least  days must have elapsed after allogeneic bone marrow transplant or stem cell infusion prior to study drug administration
Patients who have undergone allo-stem cell transplant (SCT) are eligible if they are at least  months post SCT, have relapsed AML, are not on treatment or prophylaxis for graft versus host disease (GVHD), and have no active GVHD.
Patients with a prior allogeneic transplant ARE eligible UNLESS previously or currently experienced graft versus host disease (GvHD) that required systemic steroids or other systemic lymphotoxic therapy
Patients with hematologic malignancies status post allogeneic SCT without evidence of disease relapse, active graft versus host disease (GVHD) or history of more than stage I skin acute GVHD; and off immunosuppression for at least  weeks; at least  days after allo-SCT
Patients who are <  days post allogeneic stem cell transplant will be excluded; patients beyond  days post-allogeneic stem cell transplant with active uncontrolled graft versus host disease (GVHD) > grade  will be excluded; patients who are on a stable dose of immunosuppressive therapy (tacrolimus, cyclosporine, or other) for >  weeks will be eligible but those with recent increase in the immunosuppressive medication dose within last  weeks to control GVHD will not be included; Note: subjects may be using systemic corticosteroids or topical or inhaled corticosteroids post allogeneic stem cell transplant; patients requiring >=  mg/kg prednisone for GVHD management at the time of screening will not be eligible until the prednisone can be weaned to <  mg/kg; such patients should be monitored for at least  days and if no flare of GVHD requiring re-escalation of steroids or additional interventions for the GVHD they will be eligible
Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:\r\n* =<  days from allogeneic SCT \r\n* Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD
Patient participants who have undergone allogeneic SCT (alloSCT) are eligible if they are >=  days from stem cell infusion, have no evidence of graft versus host disease (GVHD) > grade , and are >=  weeks off all immunosuppressive therapy
Patients with previous allogeneic stem cell transplant (SCT) are excluded within  months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for graft versus host disease (GVHD) for at least  days before cycle  day
Patients with relapsed disease after prior allogeneic SCT (myeloablative or nonmyeloablative) will be eligible if they meet all other inclusion criteria and:\r\n* Have no active graft versus host disease (GVHD) and require no immunosuppression\r\n* Are more than  months from transplant
Have undergone autologous or allogeneic stem cell transplant < days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy or are being considered for stem cell transplant within - months of enrollment (note: ponatinib is not to be used as a bridge to stem cell transplant in this trial)
Participants who are less than  days post-transplant, or greater than  days post-transplant with active graft versus host disease (GVHD), or are still continuing post-transplant immunosuppressant therapy within  days prior to the first dose of study drug.
Prior allogeneic transplant with graft-versus-host disease (GVHD) requiring ongoing immunosuppressive therapy
Patients with previous allogeneic stem cell transplant (SCT) within  months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for graft-versus host disease (GVHD) for at least  days before cycle  day 
Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:\r\n* <  days from allogeneic SCT\r\n* Active acute or chronic graft-versus-host disease (GvHD), or\r\n* Receiving immunosuppressive therapy as treatment for GvHD within the last  days
Prior allogeneic transplant with graft-versus-host disease (GVHD) requiring immunosuppressive therapy
If a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for graft versus host disease (GVHD) for at least  weeks before undergoing leukapheresis\r\n* Note: the above is not applicable if the research participant's done is undergoing leukapheresis
If a research participant has undergone prior allogeneic stem cell transplant (alloSCT), and has documented =< grade  graft versus host disease (GVHD) but the donor is undergoing leukapheresis, the research participant may be considered eligible for enrollment (at the discretion of the study principal investigator [PI]) provided that immunosupressants can be tapered off completely prior to lymphodepletion
Patients with relapsed disease after prior allogeneic SCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and:\r\n* Have experienced graft rejection (no evidence of donor cells by short tandem repeat (STR) analysis on  occasions separated by at least  month)\r\n* Have no active graft-vs-host disease (GVHD) and require no immunosuppression\r\n* Are more than  months from transplant
Patients may have had a prior stem cell transplant (autologous or allogeneic), however they may not have active graft-vs-host disease (GvHD), nor be on any immunosuppression
No active graft versus host disease (GVHD): patients with a history of stem cell transplant are eligible but cannot have evidence of active GVHD as determined by the investigator
Previous allogeneic stem cell transplant within  months prior to enrolment, active graft vs host disease (GVHD), or requiring transplant-related immunosuppression
Subjects after prior allogeneic SCT are allowed if the allogeneic transplant was performed >= years prior to study treatment, and if subject has no active Graft-versus- host disease (GVHD) requiring treatment, and meet the remaining eligibility criteria.
Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).
Prior allogeneic stem cell transplant with day  <  months prior and/or with chronic graft versus host disease (GVHD) requiring current use of immunosuppression; patients with prior allogeneic stem cell transplant with day  >  months prior who do not require immunosuppression for GVHD will be eligible
Recipients of previous allogeneic transplants who have rash involving more than % body surface area attributed to graft versus host disease (GVHD) (> grade  GVHD of skin); stem cell transplant recipients will be excluded if they are still receiving immunosuppression including steroids for GVHD or have active GVHD in any organ (except for grade  only of skin, not requiring treatment)
Active, uncontrolled graft vs. host disease (GVHD) following allogeneic transplant for non-AML condition (e.g. MDS, lymphoid malignancy, aplastic anemia); patients with GVHD controlled on stable doses of immunosuppressants are eligible
At least one prior therapy for CLL/SLL; prior autologous or allogeneic stem cell transplant is allowed; patients may not be on chronic immunosuppressive therapy for graft-versus-host disease (GVHD); patients who are on only oral steroids must be on an oral dose of mg or less of prednisone (or equivalent) daily
Patients who have undergone allogeneic SCT (alloSCT) are eligible if they are >=  days post stem cell infusion, have no evidence of graft-versus-host disease (GVHD) > grade , and are >=  weeks off all immunosuppressive therapy
Patients with an allogeneic transplant must meet the following conditions: the transplant must have been performed more than  days before registration to this study, the patient must not have >= grade  acute graft versus host disease (GvHD) or either moderate or severe limited chronic GvHD, or extensive chronic GvHD of any severity; the patient must be off all immunosuppression for at least  weeks
Patients with history of allogeneic stem cell transplantation are eligible if at least  days post-transplant, if there is no evidence of active graft-versus-host disease (GVHD) and no longer taking immunosuppressive agents for at least  days prior to enrollment
Prior allogeneic bone marrow progenitor cell transplant within  days or on active immunosuppression for graft versus host disease (GVHD) treatment or prophylaxis within  days prior to enrollment
If participant had prior allogeneic stem cell transplant (SCT), participant has evidence of ongoing graft-versus-host disease (GvHD).
Patients with relapsed disease after prior allogeneic SCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and\r\n* Have no active graft-versus-host disease (GVHD) and require no immunosuppression\r\n* Are more than  months from transplant
Patients with previous allogeneic stem cell transplant (SCT) within  months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for GVHD for at least  days before cycle  day 
Subjects can be enrolled and treated under this protocol regardless of their CLL treatment history or number of previous treatments; in addition, subjects with history of allogeneic stem cell transplant can be enrolled and treated unless they have active manifestations of graft versus (vs.) host disease (GVHD) or chronic illness or infections that will prevent them from completing the study
Active graft-versus-host disease (GVHD) following allogeneic stem cell transplant for non-AML condition (ex. MDS, MPN, lymphoid malignancy, aplastic anemia) requiring ongoing use of immunosuppressants
Patients within  year of allogeneic stem cell transplant, patients with active graft versus host disease (GVHD) or requiring immunosuppression are excluded
Patients with relapsed disease after prior allogeneic SCT (myeloablative or nonmyeloablative) will be eligible if they meet all other inclusion criteria and:\r\n* Experienced graft rejection (no evidence of donor cells by short tandem repeat [STR] analysis on  occasions separated by at least  month)\r\n* Have no active graft-versus-host disease (GVHD) and require no immunosuppression\r\n* Are more than  months from transplant
Patients who underwent stem cell transplant (SCT) in first complete remission are eligible, as long as all of the following criteria are met:\r\n* At least  days have elapsed since stem cell infusion\r\n* At least  days off of all medications for graft-versus-host-disease (GVHD) prophylaxis or treatment\r\n* No evidence of acute GVHD
Patients previously treated with allogeneic stem cell transplant (SCT) that is currently complicated by active graft versus host disease (GVHD) requiring T cell suppressive therapy
Hematopoietic Stem Cell Transplant: Patients who have had previous allogeneic HSCT must have grade I or less of Graft-versus-Host Disease (GVHD) and have not received immunosuppressive medication for at least  days.
Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria: <  days from allogeneic SCT, acute or chronic graft-versus-host disease (GvHD), or receiving immunosuppressive therapy as treatment for or prophylaxis against GvHD within the last  days
Allogeneic stem cell transplant within  days, active acute or chronic graft-versus-host disease (GvHD), or receiving immunosuppressive therapy as treatment for GvHD
Participants who are less than  days post-transplant, or greater than or equal to  days post-transplant with active graft versus host disease (GVHD), or are receiving immunosuppressant therapy within  days prior to first dose of study drug.
Patients must have recovered from the acute side effects of all prior anticancer therapy\r\n* At least  week from prior cytotoxic chemotherapy\r\n* At least  weeks from craniospinal irradiation\r\n* At least  months since hematopoietic stem cell transplant (HSCT) with no evidence of active graft-versus-host disease (GVHD)
Patients with previous allogeneic stem cell transplant (SCT) within  months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for graft-versus host disease (GVHD) for at least  days before cycle  day 
Hematopoietic stem cell transplant recipients with chronic thrombocytopenia due to chronic graft-versus-host disease (GVHD) or other causes
Previous allogeneic hematopoietic stem cell transplant within  months prior to enrollment, active graft versus host disease (GVHD), or requiring transplant-related immunosuppression.
Prior allogeneic stem cell transplant with active graft-versus-host- disease (GVHD).
Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be ?  weeks off immunosuppressive therapy.
The patient underwent autologous or allogeneic stem cell transplant within  days prior to receiving the first dose of omacetaxine and has any evidence of ongoing graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy.
